Reovirus for the treatment of neoplasia

Details Reovirus for the treatment of neoplasia Reovirus for the treatment of neoplasia

2007-11-27

2007-11-27

Guzo, David (Department: 1636)

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Virus or bacteriophage

C424S093100, C424S093300, C424S204100, C424S215100

Reexamination Certificate

active

10403528

ABSTRACT:
Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, and use of reovirus for manufacture of a medicament for the treatment of neoplasia, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other sterotypes or strains of reovirus can be used. Combinations of more than one type and/or strain or reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.

REFERENCES:
patent: 4108983 (1978-08-01), Wallack
patent: 4205131 (1980-05-01), Almeida
patent: 4490358 (1984-12-01), Greene et al.
patent: 5525342 (1996-06-01), Rosenberger et al.
patent: 6110461 (2000-08-01), Lee et al.
patent: 6455038 (2002-09-01), Lee et al.
patent: 0453242 (1991-10-01), None
patent: 0514603 (1992-11-01), None
patent: 90/09441 (1990-08-01), None
patent: 90/11765 (1990-10-01), None
patent: 94/18992 (1994-09-01), None
patent: 97/04805 (1997-02-01), None
patent: 97/16443 (1997-05-01), None
patent: 98/08541 (1998-03-01), None
patent: 99/08692 (1999-02-01), None
patent: 99/18799 (1999-04-01), None
Andreansky, S.S. et al., “The Application of Genetically Engineered Herpes Simplex Viruses to the Treatment of Experimental Brain Tumors,”Proc. Natl. Acad. Sci. USA93:11313-11318 (1996).
Armstrong, G.D. et al.,Virology138:37 (1984).
Aronheim, A. et al., “Membrane Targeting of the Nucleotide Exchange Factor Sos Is Sufficient for Activating the Ras Signaling Pathway,”Cell78:949-961 (1994).
Avruch, J. et al., “Raf meets Ras: Completing the Framework of a Signal Transduction Pathway”,Trends Bioch. Sci.19:279 (1994).
Barbacid, M., “ras Genes,”Annu. Rev. Biochem.56:779-827 (1987).
Berrozpe, G. et al., “Comparative Analysis of Mutations in the p53 and K-rasGenes in Pancreatic Cancer,”Int. J. Cancer58:185-191 (1994).
Bischoff, J.R. et al., “Mechanism of Interferon Action, Activation of the Human P1/elF-2α Protein Kinase by Individual Reovirus s-Class mRNAs: s1 mRNA is a Potent Activator Relative to s4 mRNA,”Virology172:106-115 (1989).
Bos, J. L., “ras Oncogenes in Human Cancer: A Review,”Cancer Res.49:4682-4689 (1989).
Boviatsis, E.J. et al., “Antitumor Activity and Reporter Gene Transfer into Rat Brain Neoplasms Inoculated with Herpes Simplex Virus Vectors Defective in Thymidine Kinase or Ribonucleotide Reductase,”Gene Therapy1:323-331 (1994).
Bryson, J.S. and Cox, D.C., “Characteristics of Reovirus-mediated Chemoimmunotherapy of Murine L1210 Leukemia,”Cancer Immunol. Immunother.26:132-138 (1988).
Cahill, M. A. et al., “Signalling Pathways: Jack of all Cascades,”Current Biology, 6(1): 16-19 (1996).
Chambers, R. et al., “Comparison of Genetically Engineered Herpes Simplex Viruses for the Treatment of Brain Tumors in a SCID Mouse Model of Human Malignant Glioma,”Proc. Natl. Acad. Sci. USA92:1411-1415 (1995).
Chandran, Kartik et al., “Protease Cleavage of Reovirus Capsid Protein Mul/MulC is Blocked by Alkyl Sulfate Detergents, Yielding a New Type of Infectious Subvirion Particle”,Journal of Virology72(1):467-475 (1988).
Chaubert, P. et al., “K-ras Mutations and p53 Alterations in Neoplastic and Nonneoplastic Lesions Associated with Longstanding Ulcerative Colitis,”Am. J. Path.144:767-775 (1994).
Coffey, Matthew C. et al., “Reovirus Therapy of Tumors with Activated Ras Pathway,”Science(Washington D.C.), vol. 282, No. 5392, pp. 1332-1334 (Nov. 13, 1998).
Database Biosis ′Online!, Biosciences Information Service, Philadelphia, PA, US; 1996, Ballag Gideon et al., “Loss of NF1 Results in Activation of the Ras Signalling Pathway and Leads to Aberrant Growth in Haematopoietic Cells,”Nature Geneticsvol. 12, No. 2, 1996, pp. 144-148.
Der, S.D. et al., “A Double-Stranded RNA-activated Protein Kinase-dependent Pathway Mediating Stress-induced Apoptosis,”Proc. Natl. Acad. Sci. USA94:3279-3283 (1997).
Dudley, D.T. et al., “A Synthetic Inhibitor of the Mitogen-activated Protein Kinase Cascade,”Proc. Natl. Acad. Sci. USA92:7686-7689 (1995).
Duncan, M. R. et al., “Differential Sensitivity of Normal and Transformed Human Cells to Reovirus Infection,”J. of Virol.28 (2):444-449 (1978).
Gale, Jr. et al., “Evidence that Hepatitis C Virus Resistance to Interferon is Mediated Through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein”Virology230:217-227 (1997).
Gentsch, J.R. and Pacitti, A.F., Effect of Neuraminidase Treatment of Cells and Effect of Soluble Glycoproteins on Type 3J. Virol.56:356 (19985).
Gentsch, J.R. et al., Genetic Diversity in Natural Populations of Mammalian Reoviruses: Tryptic Peptide Analysis of Outer Capsid Polypeptides of Murine, Bovine, and Human Type 1 and 3 Reovirus Strains,Journal of Virology4:641-651 (1984).
Hall-Jackson, C.A. et al., “Induction of Cell Death by Stimulation of Protein Kinase C in Human Epithelial Cells Expressing a Mutant Ras Oncogene: A Potential Therapeutic Target,”British Journal of Cancer78:(5)641-651 (1998).
Hashiro, G. et al., “The Preferential Cytotoxicity of Reovirus for certain transformed cell lines”,Archives of Virology54(4):307-315 (1977).
He et al., “Suppression of the Phenotype of γ134.5- Herpes Simplex Virus 1: Failure of Activated RNA-dependen Protein Kinase to Shut Off Protein Synthesis is Associated with a Deletion in the Domain of the α47 Gene”J. of Virol.71(8):6049-6054 (Aug. 1997).
Helbing, C.C. et al., A Novel Candidate Tumor Suppressor,ING1, Is Involved in the Regulation of Apoptosis,Cancer Res. 57:1255-1258 (1997).
Hershey, J.W.B., “Translation Control in Mammalian Cells,”Annu./ Rev. Biochem.60:717-755 (1991).
Hu, Y. et al., “2-Aminopurine Inhibits the Double-Stranded RNA-Dependent Protein Kinase Both in Vitro and In Vivo,”J. Interferon Res.13:323-328 (1993).
Jackson, G.G. et al.,J. Infect. Dis.128:811-866 (1973).
Janes, P.W. et al., Activation of the Ras Signalling Pathway in Human Breast Cancer Cells OverexpressingerbB-2,Oncogene9:3601 (1994).
Kawagishi-Kobayashi et al., “Regulation of the Protein Kinase PKR by the Vaccinia Virus Pseudosubstrate Inhibitor K3L is Dependent on Residues Conserved between the K3L Protein and the pKR Substrate 31F2α”Mol and Cell Biol.17(7):4146-4158 (1997).
Kollermorgen, G.M. et al., “Immunotherapy of EL4 Lymphoma with Reovirus,”Cancer Immunol. Immunother.1:239-244 (1976).
Laemmli, U.K., “Cleavage of Structural Proteins During the Assembly of the Head of Bacteriophage T4,”Nature227:680-685 (1970).
Lee, J.M. et al. “p53 Mutations Increase Resistance to Ionizing Radiation,”Proc. Natl. Acad. Sci. USA, 90:5742-5746 (1993).
Lee, P.W.K. et al., “Characterization of Anti-Reovirus Immunoglobulins Secreted by Cloned Hybridoma Cell Lines,”Virology108:134-146 (1981).
Levitzki, A., “Signal-transduction Therapy, A Novel Approach to Disease Management,”Eur. J. Biochem. 226:1-13 (1994).
Lowe, S.W. et al., “p53 Status and the Efficacy of Cancer Therapy in Vivo,”Science266:807-810 (1994).
Macara, I. G. et al., “The Ras Superfamily of GTPases,”The FASEB Journal10:625-630 (1996).
Marshall, C.J., “Ras Effectors,”Current Opinion in Cell Biology8:197-204 (1996).
McRae, M.A. et al., “The Nature of the Polypeptide Encoded by Each of the 10 Double-Stranded RNA Segments of Reovirus Type 3,”Virology89:578-593 (1978).
Mills, N.E. et al., “Increased Prevalence of K-ras Oncogene Mutations in Lung Adenocarcinoma,”Cancer Res.55:1444-1447 (1995).
Mundschau, L.J. et a

Affiliated with

Also associated with

Rating

Reovirus for the treatment of neoplasia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Reovirus for the treatment of neoplasia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Reovirus for the treatment of neoplasia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3838489